Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders
Kai Zhang, Xiaoqin Zhou, Huanzhong Liu, Kenji Hashimoto
Abstract
Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.
Topics & Concepts
EscitalopramOlanzapineCitalopramPsychiatryTolerabilityMedicineCoronavirus disease 2019 (COVID-19)Schizophrenia (object-oriented programming)PharmacologyAdverse effectInternal medicineAntidepressantAnxietyInfectious disease (medical specialty)DiseaseLong-Term Effects of COVID-19Pharmacological Receptor Mechanisms and EffectsTryptophan and brain disorders